DYAI - שווי פעילות Dyadic International

The historical Enterprise Value price action for Dyadic International (DYAI) stands at 17.05. Dyadic International (DYAI) is currently implementing protein synthesis systems, relying on partner grants prior to the launch of its primary cash flow. The technology stack is based on automated bioreactors, although final control remains with experts. Business development is accelerating through licensing alliances with biopharma behemoths to create effective vaccines.

Institutional capital assesses the investment attractiveness of Dyadic International (DYAI) through the lens of total enterprise value. The company's enterprise value (EV) is calculated as the sum of market capitalization and net debt, excluding cash. The current value of 17.05 reflects the actual cost of acquiring the asset. For this innovative developer of protein platforms, this indicator confirms the capitalization of its technological advantage. The stability of this metric guarantees the fundamental resilience of the biotechnology brand.